The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 992-995

  Burke, Michael J ^a   Willert, Jennifer ^b   Desai, Sunil ^c   Kadota, Richard ^b  

^a University of Minnesota Children's Hospital   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c STOLLERY CHILDREN S HOSPITAL   (Canada)

Author keywords

ALL; BMT; CML; Stem cell transplant

Indexed keywords

IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANADA; CANCER REGRESSION; CANCER RELAPSE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COMPARATIVE STUDY; DONOR; HUMAN; MAINTENANCE THERAPY; PEDIATRIC HOSPITAL; PEDIATRICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING; UNITED STATES;

CANADA; DATA COLLECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; SIBLINGS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 71049160882     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22172     Document Type: Article

References (23)

1. Goldman JM. HowI treat chronic myeloid leukemia in the imatinib era. Blood 2007;110:2828-2837.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
3. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686-4692.
4. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006.
5. Uckun FM, Nachman JB, Sather HN, et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group. Cancer 1998;83: 2030-2039.
6. Sharathkumar A, Saunders EF, Dror Y, et al. Allogeneic bone marrow transplantation versus chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2004;33:39-45.
7. Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood 1997;90:1410-1414.
8. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 2007;109:1408-1413.
9. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105: 3449-3457.
10. Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005;130:489-500.
11. Schultz KR, Bowman WP, Slayton W, et al. Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031. Blood 2007;110:4.
12. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791-2793.
13. Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007;110:4614-4617.
14. Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003;102:1224-1231.
15. Unal S, Fidan G, Tavil B, et al. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience. Pediatr Transplant 2007;11:645-649.
16. Fuster JL, Bermudez M, Galera A, et al. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2007;92:1723-1724.
17. Pulsipher MA. Treatment of CML in pediatric patients: Should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer 2004; 43:523-533.
18. Thornley I, Perentesis JP, Davies SM, et al. Treating children with chronic myeloid leukemia in the imatinib era: A therapeutic dilemma? Med Pediatr Oncol 2003;41:115-117.
19. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-2660.
20. Lee SJ, Kukreja M,Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008;112:3500-3507.
21. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004;18:1332-1339.
22. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications. Cancer 2008;112:2112-2118.
23. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-1930.